Cargando…

Anti CD38 monoclonal antibodies for multiple myeloma treatment

CD38 is a transmembrane glycoprotein with ectoenzymatic activity and is highly and uniformly expressed on multiple myeloma (MM) cells. CD38 is expressed also at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of non-hematopoietic origin. The specificity of this target...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gozzetti, Alessandro, Ciofini, Sara, Simoncelli, Martina, Santoni, Adele, Pacelli, Paola, Raspadori, Donatella, Bocchia, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Immunotherapeutics – Product Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225612/ https://www.ncbi.nlm.nih.gov/pubmed/35404740 http://dx.doi.org/10.1080/21645515.2022.2052658

Ejemplares similares

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI
por: Santoni, Adele, et al.
Publicado: (2022)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Update about Oralair® as a treatment for grass pollen allergic rhinitis
por: Klimek, L., et al.
Publicado: (2022)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development
por: Hicks, Dustin, et al.
Publicado: (2022)

A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
por: Cencini, Emanuele, et al.
Publicado: (2021)

Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications
por: Cencini, Emanuele, et al.
Publicado: (2023)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Steps towards a Multiple Myeloma Cure?
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

CD26/DPP-4 in Chronic Myeloid Leukemia
por: Sicuranza, Anna, et al.
Publicado: (2022)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Immunotherapy of glioblastoma: Recent advances and future prospects
por: Yuan, Boyang, et al.
Publicado: (2022)

The progress of peptide vaccine clinical trials in gynecologic oncology
por: Tang, Mi, et al.
Publicado: (2022)

Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines’ immunogenicity
por: Scendoni, Roberto, et al.
Publicado: (2022)

Review of bimekizumab in the treatment of psoriasis
por: Koppu, Sindhuja, et al.
Publicado: (2022)

Therapeutic potential of mesenchymal stem cells for refractory inflammatory and immune skin diseases
por: Hua, Chunting, et al.
Publicado: (2022)

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
por: Asmamaw Dejenie, Tadesse, et al.
Publicado: (2022)

Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives
por: Nagata, Yusuke, et al.
Publicado: (2022)

The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies
por: Ling, Qiaoyun, et al.
Publicado: (2022)

Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer
por: Zhu, Yahui, et al.
Publicado: (2022)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Waning of maternal antibody against measles virus in Shufu, China
por: He, Qing, et al.
Publicado: (2022)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

Monitoring of molecular profiling of allergen-antibody responses in HDM-immunotherapy patients
por: Nittner-Marszalska, Marita, et al.
Publicado: (2022)

Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8+ T cells with a regulatory phenotype
por: Elizondo, C. Riccay, et al.
Publicado: (2022)

Flow Cytometry Assessment of CD26(+) Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia
por: Raspadori, Donatella, et al.
Publicado: (2019)

Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study
por: Del Giudice, Maria Livia, et al.
Publicado: (2022)

Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients
por: Ippoliti, Micaela, et al.
Publicado: (2012)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2016)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
por: Resch, Bernhard
Publicado: (2017)

Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26(+) leukemia stem cells
por: Pacelli, Paola, et al.
Publicado: (2023)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
por: Antonioli, Elisabetta, et al.
Publicado: (2023)

Single Agent Lenalidomide Activity in Multiple Myeloma Relapse Evidenced Uniquely by CT/PET
por: Gozzetti, Alessandro, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bfm986l8qinoub9r6mk4lvju2i